Tegrad (Dolutegravir)

Dolutegravir is a potent integrase strand transfer inhibitor designed to manage HIV infection by blocking the enzyme that allows the virus to replicate within your body. This antiretroviral medication works at the molecular level to reduce viral load and help restore immune function, making it an essential component of modern HIV treatment regimens.

Typically administered at 50mg once daily for treatment-naive patients, or adjusted dosing for those with integrase resistance, dolutegravir offers convenient once-daily dosing that supports treatment adherence. The medication demonstrates superior efficacy compared to older antiretroviral classes, with rapid viral suppression achievable within weeks of consistent use.

Common side effects are generally mild and manageable, including headache, nausea, and diarrhea, which often diminish over time. Some patients report dizziness or sleep disturbances, though serious adverse effects remain uncommon. Weight gain has been observed in certain individuals, particularly when combined with specific nucleoside backbones. This integrase inhibitor represents a significant advancement in HIV therapy, offering both efficacy and tolerability that empower patients to maintain undetectable viral loads and achieve long-term health outcomes.

When taken as prescribed with a complete antiretroviral regimen, it provides reliable viral suppression and helps prevent disease progression.